C1Q-FIXING HLA ANTIBODIES AND KIDNEY TRANSPLANTATION (Abstract/Comunicazione in rivista)

Type
Label
  • C1Q-FIXING HLA ANTIBODIES AND KIDNEY TRANSPLANTATION (Abstract/Comunicazione in rivista) (literal)
Anno
  • 2012-01-01T00:00:00+01:00 (literal)
Alternative label
  • Elvira Poggi 1, Giuseppina Ozzella 1, Daniela Caputo 2, Rosa Cremona 2, Cecilia Palombi 2, Annarita Manfreda 2, Domenico Adorno 2, Antonina Piazza 1. (2012)
    C1Q-FIXING HLA ANTIBODIES AND KIDNEY TRANSPLANTATION
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Elvira Poggi 1, Giuseppina Ozzella 1, Daniela Caputo 2, Rosa Cremona 2, Cecilia Palombi 2, Annarita Manfreda 2, Domenico Adorno 2, Antonina Piazza 1. (literal)
Pagina inizio
  • 37 (literal)
Pagina fine
  • 37 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#altreInformazioni
  • oral presentation (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 73 (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali
  • 1 (literal)
Note
  • Comunicazione (literal)
  • Google Scholar (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • 1 Institute of Translational Pharmacology, Unit of Rome S. Camillo Hospital, National Council of Researches, Rome, Italy; 2 Regional Transplant Center of Lazio, Tor Vergata University of Rome, Rome, Italy. (literal)
Titolo
  • C1Q-FIXING HLA ANTIBODIES AND KIDNEY TRANSPLANTATION (literal)
Abstract
  • Aim: De novo production of donor-specific HLA antibodies (DSA) represents the major risk factor of graft failure in kidney transplantation. However, some patients show persistent presence of circulating DSA without occurrence of graft dysfunction/loss. Newer solid phase assay Luminex Single Antigen (LSA) beads, is highly sensitive respect to complement-dependent citotoxicity assay but less predictive of transplant outcome because of detection of both complement-fixing and less clinically relevant no complement-fixing HLA antibodies. Methods: Using Class I and II C1q-LSA assay (One Lambda,CA), that identifies antibodies able to fix C1q, we investigate the clinical relevance of de novo HLA-DSA in 40 kidney transplanted patients. As for transplant outcome, 22 patients suffered graft failure (within 10 ± 1 months from DSA appearance) and 18 had good graft function during all the follow up (mean 54 ± 34 months from DSA appearance). Results: Twenty-three patients showed production of C1q-positive DSA while 17 produced C1q-negative DSA. Correlating graft outcome and capability of DSA to fix C1q, graft failure occurred in 20/23 C1q-positive DSA patients; only 2/17 C1q-negative DSA patients suffered graft failure (87% vs.12%, P < 0.0001; RR = 7.39; Sensitivity = 0.91; Specificity = 0.83; PPV = 0.87; NPV = 0.88). It is to underlay that both C1q-positive and C1q-negative DSA were mainly specific for DQ donor mismatched molecules (74% vs. 53%); the 53% of anti-DQ C1q-positive DSA were specific for DQ1 molecules while the 75% of anti-DQ C1q-negative DSA were specific for DQ2 molecules. Conclusions: C1q-LSA assay showed the capability to identify the subset of IgG-LSA DSA strongly associated to antibody-mediated rejection and graft loss in kidney transplantation; moreover, its ability in distinguishing less harmful no complement-fixing DSA from clinically relevant C1q-fixing DSA, allows to identify patients that need specific immunosuppressive strategy to prolong graft survival. (literal)
Editore
Prodotto di
Autore CNR

Incoming links:


Autore CNR di
Prodotto
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
Editore di
data.CNR.it